Email
IZ Express #1,622: CDC publishes ACIP recommendations for licensed Moderna COVID-19 Vaccine (Spikevax), and more.
| From | Immunization Action Coalition <[email protected]> |
| Subject | IZ Express #1,622: CDC publishes ACIP recommendations for licensed Moderna COVID-19 Vaccine (Spikevax), and more. |
| Date | March 23, 2022 10:00 AM |
Links have been removed from this email. Learn more in the FAQ.
Links have been removed from this email. Learn more in the FAQ.
[link removed]
[link removed]
[link removed]
[link removed] [link removed]
Email not displaying correctly? View it in your browser ([link removed]).
[link removed]
Issue 1,622: March 23, 2022 Formerly IAC Express
Top Stories
* “The Advisory Committee on Immunization Practices Recommendation for Use of Moderna COVID-19 Vaccine in Persons Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines—United States, February 2022” published in MMWR
* “Effectiveness of mRNA Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death—United States, March 2021–January 2022” published as an MMWR Early Release
* CDC revises two tables in its General Best Practice Guidelines for Immunization
* Order today! Laminated versions of CDC’s 2022 immunization schedules are available to ship.
* Spotlight: Review of resources at Immunize.org focused on communications
* AAP posts analysis of COVID-19 vaccination trends in U.S. children and adolescents
* Influenza activity is low overall, but continues to increase in some parts of the country. Keep offering to vaccinate.
* Immunize.org’s Hepatitis B Birth Dose Honor Roll recognizes 546 institutions, including one new honoree. Six previously honored institutions qualify for additional years' honors.
* Vaccines in the news
Immunize.org Pages and Handouts
* Reminder: Immunize.org updates two of its popular standing order templates with new CDC recommendations: pneumococcal vaccination of adults and zoster (shingles) vaccination
* Reminder: "Ask the Experts: Zoster" web page updated with new clinical considerations for vaccination of immunocompromised adults age 19 and older
Vaccine Information Statements
* Reminder: Immunize.org posts new Vaccine Information Statements (VISs) in nine languages for pneumococcal conjugate vaccine (PCV) and recombinant zoster (shingles) vaccine
Featured Resources
* 65+ Flu Defense website offers resources for healthcare professionals serving older adults
Notable Publications
* "Trends in Human Papillomavirus–Associated Cancers, Demographic Characteristics, and Vaccinations in the U.S., 2001–2017" published in JAMA Network
Upcoming Events
* Virtual: Nevada Immunization Learning Exchange offers webinar, “Overview for Parents and Caregivers: The COVID-19 Vaccine for Children and Youth with Special Health Care Needs including Children Living with Intellectual and Developmental Disabilities,” on March 29
------------------------------------------------------------
Top Stories
------------------------------------------------------------
“The Advisory Committee on Immunization Practices Recommendation for Use of Moderna COVID-19 Vaccine in Persons Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines—United States, February 2022” published in MMWR
CDC published The Advisory Committee on Immunization Practices Recommendation for Use of Moderna COVID-19 Vaccine in Persons Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines—United States, February 2022 ([link removed]) in the March 18 issue of MMWR. A portion of the summary appears below.
...On February 4, 2022, after a systematic review of the evidence, the Advisory Committee on Immunization Practices issued a standard recommendation for use of the Moderna COVID-19 vaccine in persons aged ≥18 years. CDC provided guidance that an 8-week interval between primary series doses of mRNA vaccines might be optimal for some persons....
These recommendations were incorporated into the February 24 update to Immunize.org’s Ask the Experts: COVID-19 ([link removed]) page. Access the MMWR article in HTML ([link removed]) or PDF ([link removed]).
Related Links
* MMWR's main page ([link removed]) provides access to MMWR Weekly and its companion publications
* Immunize.org: ACIP Recommendations ([link removed]) main page
* Immunize.org: Ask the Experts COVID-19 ([link removed]) page
* Immunize.org: Vaccines: COVID-19 ([link removed]) main page
* Immunize.org: Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools ([link removed])
* CDC: Interim Clinical Considerations ([link removed]) page
------------------------------------------------------------
“Effectiveness of mRNA Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death—United States, March 2021–January 2022” published as an MMWR Early Release
CDC published Effectiveness of mRNA Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death—United States, March 2021–January 2022 ([link removed]) on March 18 as an MMWR Early Release. A portion of the summary appears below.
...Receiving 2 or 3 doses of an mRNA COVID-19 vaccine was associated with a 90% reduction in risk for COVID-19–associated IMV or death. Protection of 3 mRNA vaccine doses during the period of Omicron predominance was 94%....
The effectiveness of 2 or 3 doses of COVID-19 mRNA vaccines against COVID-19–associated invasive mechanical ventilation or in-hospital death was high for:
* People age 18–64 years (91%) and those older than age 64 years (88%)
* People who are immunocompetent (92%) and those who are immunocompromised (74%)
* Immunocompetent people with zero (98 %), one (95%), two (89%), or more than two (84%) chronic conditions
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]).
Related Link
* MMWR's main page ([link removed]) provides access to MMWR Weekly and its companion publications
------------------------------------------------------------
CDC revises two tables in its General Best Practice Guidelines for Immunization
On March 18, CDC updated the list of errata/updates ([link removed]) in its General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP) ([link removed]). The updates include the definitions of new terms used to describe vaccine categories (including non-live and non-replicating), and new information about contraindications to dengue vaccination. Specific information from CDC about the recent updates appears below.
Timing and Spacing of Immunobiologics
Table 3-1 (callout from PAGE 12)
A new table has been added (check renumbering if you’ve exported stand-alone documents). The new table highlights categories of vaccines (with callout from text on page 12). There are four categories: live; live-attenuated; non-live; and non-replicating. …
Contraindications and Precautions
Table 4-1
In the row for dengue vaccine, information has been added specifying that dengue vaccine should be used only in persons in endemic areas who have evidence of prior infection with dengue virus. Additionally, “Lack of laboratory evidence of previous dengue infection” has been added as a contraindication to dengue vaccine.
Related Link
* CDC: General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP) ([link removed])
------------------------------------------------------------
Order today! Laminated versions of CDC’s 2022 immunization schedules are available to ship.
Immunize.org laminated versions of the 2022 U.S. child and adolescent immunization schedule ([link removed]) and the 2022 U.S. adult immunization schedule ([link removed]) are available for preorder and will ship this week.
While the schedules are available online from CDC at no cost, Immunize.org’s printed, laminated schedules are ideal for use in any busy healthcare setting where vaccinations are given. Their tough coating can be wiped down, and they’re durable enough to stand up to a year's worth of use.
In 2022, the length of each schedule with appendices was extended by two pages. As a result, the laminated schedules are now published in a standard 8.5” X 11” booklet format.
* The child/adolescent schedule booklet is ten pages (i.e., five double-sided pages) and includes a bonus page with Immunize.org’s popular 1-page handout summarizing the dose, route, and needle size recommendations for all vaccines and recipients
* The adult schedule booklet is eight pages (i.e., four double-sided pages)
With color coding for easy reading, our laminated schedules replicate the original CDC formatting, including the essential tables and notes.
PRICING
Number of Copies Cost
1–4 copies $7.50 each
5–19 copies $5.50 each
20–99 copies $4.50 each
100–499 copies $4.00 each
500–999 copies $3.50 each
For quotes on customizing or placing orders of 1,000 copies or more, call 651-647-9009 or email [email protected].
Visit the Shop Immunize.org: Laminated Schedules ([link removed]) web page for more information on the schedules, to view images of all the pages, to download the order form, and to order today!
Related Links
* Immunize.org: Laminated Child and Adolescent Immunization Schedules (0–18 years) ([link removed]) web page
* Immunize.org: Laminated Adult Immunization Schedules (19 and older) ([link removed]) web page
* Immunize.org: Shop Immunize.org ([link removed]) main page
------------------------------------------------------------
Spotlight: Review of resources at Immunize.org focused on communications
In this week's Immunize.org Spotlight, we summarize resources at Immunize.org that focus on communication between healthcare personnel, patients, and caregivers.
Immunize.org's Talking about Vaccines ([link removed]) web section provides healthcare professionals with 11 topical web pages to help them discuss immunization with concerned parents or patients. Examples include “Adjuvants,” “Alternative Medicine,” “Autism,” “Religious Concerns,” and “Thimerosal.”
Unprotected People Stories ([link removed]) features 109 real-life accounts of people who suffered or died from vaccine-preventable diseases.
Handouts for Patients and Staff ([link removed]) leads to hundreds of patient handouts and fact sheets for healthcare professionals. All items are free to download, print, copy, and distribute widely.
Ask the Experts ([link removed]) provides more than 1,100 timely questions and answers on specific diseases and their vaccines as well as vaccine delivery guidance (e.g., administration, billing, documenting).
Vaccine Basics: Common Questions about Vaccines ([link removed]) offers patients and caregivers timely, accurate, and factual information about vaccines and the diseases they prevent.
------------------------------------------------------------
AAP posts analysis of COVID-19 vaccination trends in U.S. children and adolescents
Drawing on data collected and published by CDC, AAP is analyzing progress in vaccinating U.S. children younger than age 18 years in a new weekly summary report titled Children and COVID-19 Vaccinations Trends ([link removed]). The report covers the vaccine data available for children age 5–11 years, and the longer-term data for children age 12–17 years.
To download the full report with its useful graphics, click on the image below.
[link removed]
Related Links
* AAP: Children and COVID-19 Vaccinations Trends ([link removed]) report web page
* AAP: Children and COVID-19 Vaccinations Trends ([link removed]) full report
* CDC: COVID Data Tracker ([link removed]) main page
------------------------------------------------------------
Influenza activity is low overall, but continues to increase in some parts of the country. Keep offering to vaccinate.
Influenza Surveillance
For week 9, ending on March 5, CDC's Weekly U.S. Influenza Surveillance Report, FluView ([link removed]) summary reports that seasonal influenza activity in the United States is low but continues its gradual increase in parts of the country. The levels of acute respiratory illness reflected in the national map include both influenza and non-influenza (e.g., COVID-19) respiratory illnesses.
Influenza Vaccination Dashboard
CDC's new Weekly Flu Vaccination Dashboard ([link removed]) shares preliminary vaccination data. This week’s key fact: coverage this season (as of February 12) is 11.0 percentage points lower for non-Hispanic Black children compared with non-Hispanic White children (42.9% compared to 53.9%).
CDC recommends everyone age 6 months and older get an annual influenza vaccine. Influenza and COVID-19 vaccines may be given at the same visit, if needed. COVID-19 vaccination alone provides no protection from influenza or any other respiratory virus.
Vaccine Finder
If you don’t provide influenza vaccine at your site, please strongly recommend vaccination and refer people to sites that do vaccinate. Use VaccineFinder, a user-friendly website to help people of all ages find influenza, COVID-19, and other vaccines ([link removed]). Participating providers can update their vaccine inventory estimates on VaccineFinder. For questions or more information, contact [email protected].
Related Links
* CDC: Weekly Flu Vaccination Dashboard ([link removed]) main page
* CDC: FluView ([link removed]) main page
* CDC: Influenza (Flu) ([link removed]) main page
* Immunize.org: free educational materials and patient handouts related to influenza ([link removed])
* Immunize.org: Vaccines: Influenza ([link removed]) main page
* Immunize.org: Ask the Experts: Influenza ([link removed]) main page
* VaccineFinder ([link removed]) website
* Families Fighting Flu: Flu Resources for Healthcare Professionals ([link removed]) main page
------------------------------------------------------------
Immunize.org’s Hepatitis B Birth Dose Honor Roll recognizes 546 institutions, including one new honoree. Six previously honored institutions qualify for additional years' honors.
Immunize.org is pleased to announce that one new institution has been accepted into its Hepatitis B Birth Dose Honor Roll ([link removed]), for a total of 546 honorees. The birthing institutions are listed below with their reported hepatitis B birth dose coverage rates in parentheses.
* Erlanger Medical Center, Chattanooga, TN (95%)
One institution is being recognized for a second year:
* Bellevue Woman’s Center, Niskayuna, NY (94%)
Three institutions are being recognized for a fourth year:
* Central Vermont Medical Center, Berlin, VT (93%)
* HealthPark Medical Center, Ft. Myers, FL (90%)
* Lawrence General Hospital, Lawrence, MA (98%)
One institution is being recognized for a fifth year:
* RAF Lakenheath Hospital (U.S. Air Force), Brandon, England (93%)
Finally, one institution is being recognized for a sixth year:
* Integris Grove Hospital, Grove, OK (96%)
The Honor Roll now includes 546 birthing institutions from 44 states, the District of Columbia, Puerto Rico, Guam, Saipan, and a U.S. military base in England. One hundred twenty-three institutions have qualified for two years, 71 institutions have qualified three times, 42 institutions have qualified four times, 26 institutions have qualified five times, 23 institutions have qualified six times, 11 institutions have qualified seven times, two institutions have qualified eight times and one institution has qualified nine times.
The Honor Roll is a key part of Immunize.org’s major initiative urging the nation’s hospitals to Give Birth to the End of Hep B ([link removed]) . Hospitals and birthing centers are recognized for attaining high coverage rates for administering hepatitis B vaccine at birth and meeting specific additional criteria. The initiative urges qualifying healthcare organizations to apply for the Hepatitis B Birth Dose Honor Roll online ([link removed]).
To be included in the Hepatitis B Birth Dose Honor Roll, a birthing institution must have: (1) reported a coverage rate of 90% or greater, over a 12-month period, for administering hepatitis B vaccine before hospital discharge to all newborns, including those whose parents refuse vaccination, and (2) implemented specific written policies, procedures, and protocols to protect all newborns from hepatitis B virus infection before hospital discharge.
Honorees are also awarded an 8.5" x 11" color certificate suitable for framing and their acceptance is announced to IZ Express’s 53,000+ readers.
Please visit the Hepatitis B Birth Dose Honor Roll web page ([link removed]) that lists these institutions and their exceptional efforts to protect infants from perinatal hepatitis B transmission.
Related Immunize.org Resources
* Give Birth to the End of Hep B ([link removed]) main page
* Fact sheet about honor roll: Do You Qualify for the Hepatitis B Birth Dose Honor Roll? If So, Apply Today. ([link removed])
* Handout on Immunize.org’s campaign: Give Birth to the End of Hep B ([link removed])
* Hepatitis B Birth Dose Honor Roll ([link removed]) web page
------------------------------------------------------------
Vaccines in the news
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
* The Atlantic: America’s Flu-Shot Problem Is Also Its Next COVID-Shot Problem ([link removed]) (3/18/22)
* Washington Post: Moderna Seeks FDA Authorization for a Second Booster Dose of Its Coronavirus Vaccine for All Adults ([link removed]) (3/17/22)
* New York Times: As Virus Data Mounts, the J.&J. Vaccine Holds Its Own ([link removed]) (3/15/22)
* Becker's Hospital Review: Pfizer Seeks 2nd Booster Shot OK for People 65 and Older ([link removed]) (3/15/22)
* New York Times: In Africa, a Mix of Shots Drives an Uncertain COVID Vaccination Push ([link removed]) (3/15/22)
* The Atlantic: Vaccinating Kids Has Never Been Easy ([link removed]) (3/10/22)
------------------------------------------------------------
Immunize.org Pages and Handouts
------------------------------------------------------------
Reminder: Immunize.org updates two of its popular standing order templates with new CDC recommendations: pneumococcal vaccination of adults and zoster (shingles) vaccination
Immunize.org recently revised its Standing Orders for Administering Pneumococcal Vaccines (PCV15, PCV20, and PPSV23) to Adults ([link removed]) and Standing Orders for Administering Recombinant Zoster Vaccine to Adults ([link removed]) templates.
The Standing Orders for Administering Pneumococcal Vaccines (PCV15, PCV20, and PPSV23) to Adults ([link removed]) template incorporates the new CDC recommendations published in January 2022. This template covers the use of 15-valent pneumococcal conjugate vaccine (PCV15, Vaxneuvance, Merck), PCV20 (Prevnar20, Pfizer), and 23-valent pneumococcal polysaccharide vaccine (PPSV23, Pneumovax 23, Merck). The document outlines what to do for previously unvaccinated adults, as well as adults with a history of vaccination with PCV13 and/or PPSV23.
The Standing Orders for Administering Recombinant Zoster Vaccine to Adults ([link removed]) template was updated with information on the new CDC recommendations for use of recombinant zoster vaccine (RZV, Shingrix, GSK) in adults age 19 and older who are or will be immunodeficient or immunosuppressed as a result of disease or therapy. For patients in this category, the standing orders recommend consultation with the medical director and—as needed—the provider primarily responsible for managing the patient’s immunocompromising condition or therapy. This is because the complex and highly variable nature of immunocompromising conditions may affect the optimal timing of vaccination.
Related Links
* Immunize.org: Standing Orders for Administering Pneumococcal Vaccines (PCV15, PCV20, and PPSV23) to Adults ([link removed])
* Immunize.org: Standing Orders for Administering Recombinant Zoster Vaccine to Adults ([link removed])
* Immunize.org: Using Standing Orders for Administering Vaccines: What You Should Know ([link removed])
* Immunize.org: 10 Steps to Implementing Standing Orders for Immunization in Your Practice Setting ([link removed])
* Immunize.org: Standing Orders Templates for Administering Vaccines ([link removed]) web page
* Immunize.org: Ask the Experts: Zoster ([link removed]) web page
------------------------------------------------------------
Reminder: "Ask the Experts: Zoster" web page updated with new clinical considerations for vaccination of immunocompromised adults age 19 and older
Immunize.org thoroughly reviewed and updated its popular Ask the Experts: Zoster ([link removed]) web page on March 9. This extensive list of clinical questions and answers was updated to incorporate new ACIP recommendations and clinical considerations for the use of recombinant zoster vaccine (RZV, Shingrix, GSK) in adults age 19 years and older who are or will be immunodeficient or immunosuppressed as a result of disease or therapy. The section addresses challenging clinical questions, such as:
* Do immunocompromised adults need to be screened for immunity to varicella zoster virus?
* What do I do with an adult who never had chickenpox and only had one dose of varicella vaccine?
* Should I shorten the dosing interval if a person knows they will be starting chemotherapy soon?
Immunize.org's Ask the Experts ([link removed]) main page leads you to 30 distinct web pages on a variety of topics with more than 1,100 common or challenging questions and answers about vaccines and their administration. Immunize.org's team of experts includes Kelly L. Moore, MD, MPH (team lead), Carolyn B. Bridges, MD, FACP, and Iyabode Beysolow, MD, MPH.
Related Links
* Immunize.org: Ask the Experts: Zoster ([link removed]) web page
* Immunize.org: Ask the Experts ([link removed]) main page to answer more than 1,100 questions
------------------------------------------------------------
Vaccine Information Statements
------------------------------------------------------------
Reminder: Immunize.org posts new Vaccine Information Statements (VISs) in nine languages for pneumococcal conjugate vaccine (PCV) and recombinant zoster (shingles) vaccine
Immunize.org posted new translations of Vaccine Information Statements ([link removed]) (VISs) for Pneumococcal Conjugate Vaccine (PCV) and Recombinant Zoster (shingles) Vaccine.
All translations are available in print-ready PDF format.
VIS translations for Pneumococcal Conjugate Vaccine (PCV) ([link removed]):
* Arabic ([link removed])
* Burmese ([link removed])
* Chinese in Simplified ([link removed]) and Traditional ([link removed])
* French ([link removed])
* Russian ([link removed])
* Somali ([link removed])
* Spanish PDF ([link removed]) and RTF ([link removed])
* Vietnamese ([link removed])
VIS translations for Recombinant Zoster (shingles) Vaccine ([link removed]):
* Arabic ([link removed])
* Burmese ([link removed])
* Chinese in Simplified ([link removed]) and Traditional ([link removed])
* French ([link removed])
* Russian ([link removed])
* Somali ([link removed])
* Spanish PDF ([link removed]) and RTF ([link removed])
* Vietnamese ([link removed])
Translations of previous VIS versions may be used until new translations become available. CDC states that the corresponding up-to-date English-language VIS must also be supplied when providing an out-of-date translation.
Related Links
* Immunize.org: Vaccine Information Statement ([link removed]) main page for VISs in 46 languages ([link removed])
* Immunize.org: Dates of Current Vaccine Information Statements ([link removed]) (PDF)
* CDC: What's New with VISs ([link removed]) web page
* CDC: Current VISs ([link removed]) web page
------------------------------------------------------------
Featured Resources
------------------------------------------------------------
65+ Flu Defense website offers resources for healthcare professionals serving older adults
Confident recommendations for influenza vaccine from healthcare providers are powerfully persuasive. To assist you in maximizing protection for your patients, Immunize.org, in collaboration with Seqirus, updated the 65+ Flu Defense website at www.influenza-defense.org.
A fact sheet on the site, ([link removed]) The Importance of Preventing Influenza during a Pandemic, ([link removed]) ([link removed]) offers responses to help guide discussions with patients on the increased importance of flu vaccination during the COVID-19 pandemic. Age increases risks associated with COVID-19 infection including hospitalization and death. Preliminary studies suggest coinfection with influenza B and SARS-CoV-2 may elevate the risk of poor outcomes.
This helpful site includes information, tools, and tips for communicating with these adults about the scope and severity of influenza. Resources include:
* Influenza in Adults 65+: The Facts ([link removed])
* Influenza Vaccination: Questions Patients Age 65 and Older Frequently Ask Their HCP ([link removed])
Check out the updated 65+ Flu Defense website at www.influenza-defense.org ([link removed]) to assist your efforts in protecting this vulnerable population.
------------------------------------------------------------
Notable Publications
------------------------------------------------------------
"Trends in Human Papillomavirus–Associated Cancers, Demographic Characteristics, and Vaccinations in the U.S., 2001–2017" published in JAMA Network
In the March 16 issue, JAMA Network published Trends in Human Papillomavirus–Associated Cancers, Demographic Characteristics, and Vaccinations in the U.S., 2001–2017 ([link removed]). Before vaccination approval, cervical cancer rates in the 20- to 24-year age group were decreasing very gradually, by 2.29% annually; after vaccine approval, this rate of decrease accelerated to 9.50% annually.
The conclusions and relevance section appears below.
In the US, cervical cancer rates have decreased at a population level, especially in younger women. The findings of this study suggest this decrease may be associated with vaccination. Given the increase in oropharyngeal and anal/rectal cancers, particularly in men, it may be important to highlight vaccination uptake in both sexes.
Listen to an interview with John K. Chan, MD ([link removed]), author of this article, hosted by Angel N. Desai, MD, MPH (16:23 minutes).
------------------------------------------------------------
Upcoming Events
------------------------------------------------------------
Virtual: Nevada Immunization Learning Exchange offers webinar, “Overview for Parents and Caregivers: The COVID-19 Vaccine for Children and Youth with Special Health Care Needs including Children Living with Intellectual and Developmental Disabilities,” on March 29
Nevada Immunization Learning Exchange (NILE) will offer a webinar titled Overview for Parents and Caregivers: The COVID-19 Vaccine for Children and Youth with Special Health Care Needs including Children Living with Intellectual and Developmental Disabilities ([link removed]) on March 29 at 6:00 p.m. (PT). During this program, there will be a discussion on the impact of COVID-19 on children and youth with special healthcare needs, including children living with intellectual and developmental disabilities.
Registration is open ([link removed]) for this webinar.
------------------------------------------------------------
For more upcoming events, visit our Calendar of Events ([link removed]).
Editorial Information
Editor-in-Chief
Kelly L. Moore, MD, MPH
Managing Editor
John D. Grabenstein, RPh, PhD
Associate Editor
Sharon G. Humiston, MD, MPH
Writer/Publication Coordinator
Taryn Chapman, MS
Courtnay Londo, MA
Style and Copy Editor
Marian Deegan, JD
Web Edition Managers
Arkady Shakhnovich
Jermaine Royes
Contributing Writer
Laurel H. Wood, MPA
Technical Reviewer
Robin VanOss
About IZ Express
Immunize.org welcomes redistribution of this issue of IZ Express or selected articles.
When you do so, please add a note that Immunize.org is the source of the material and provide a link to this issue ([link removed]).
IZ Express is supported in part by Grant No. 1NH23IP922654 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.
IZ Express Disclaimer ([link removed])
ISSN: 2771-8085
To unsubscribe to this publication, go to: [link removed]
==============================================
Unsubscribe [email protected] from this list:
[link removed]
[link removed]
[link removed]
[link removed] [link removed]
Email not displaying correctly? View it in your browser ([link removed]).
[link removed]
Issue 1,622: March 23, 2022 Formerly IAC Express
Top Stories
* “The Advisory Committee on Immunization Practices Recommendation for Use of Moderna COVID-19 Vaccine in Persons Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines—United States, February 2022” published in MMWR
* “Effectiveness of mRNA Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death—United States, March 2021–January 2022” published as an MMWR Early Release
* CDC revises two tables in its General Best Practice Guidelines for Immunization
* Order today! Laminated versions of CDC’s 2022 immunization schedules are available to ship.
* Spotlight: Review of resources at Immunize.org focused on communications
* AAP posts analysis of COVID-19 vaccination trends in U.S. children and adolescents
* Influenza activity is low overall, but continues to increase in some parts of the country. Keep offering to vaccinate.
* Immunize.org’s Hepatitis B Birth Dose Honor Roll recognizes 546 institutions, including one new honoree. Six previously honored institutions qualify for additional years' honors.
* Vaccines in the news
Immunize.org Pages and Handouts
* Reminder: Immunize.org updates two of its popular standing order templates with new CDC recommendations: pneumococcal vaccination of adults and zoster (shingles) vaccination
* Reminder: "Ask the Experts: Zoster" web page updated with new clinical considerations for vaccination of immunocompromised adults age 19 and older
Vaccine Information Statements
* Reminder: Immunize.org posts new Vaccine Information Statements (VISs) in nine languages for pneumococcal conjugate vaccine (PCV) and recombinant zoster (shingles) vaccine
Featured Resources
* 65+ Flu Defense website offers resources for healthcare professionals serving older adults
Notable Publications
* "Trends in Human Papillomavirus–Associated Cancers, Demographic Characteristics, and Vaccinations in the U.S., 2001–2017" published in JAMA Network
Upcoming Events
* Virtual: Nevada Immunization Learning Exchange offers webinar, “Overview for Parents and Caregivers: The COVID-19 Vaccine for Children and Youth with Special Health Care Needs including Children Living with Intellectual and Developmental Disabilities,” on March 29
------------------------------------------------------------
Top Stories
------------------------------------------------------------
“The Advisory Committee on Immunization Practices Recommendation for Use of Moderna COVID-19 Vaccine in Persons Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines—United States, February 2022” published in MMWR
CDC published The Advisory Committee on Immunization Practices Recommendation for Use of Moderna COVID-19 Vaccine in Persons Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines—United States, February 2022 ([link removed]) in the March 18 issue of MMWR. A portion of the summary appears below.
...On February 4, 2022, after a systematic review of the evidence, the Advisory Committee on Immunization Practices issued a standard recommendation for use of the Moderna COVID-19 vaccine in persons aged ≥18 years. CDC provided guidance that an 8-week interval between primary series doses of mRNA vaccines might be optimal for some persons....
These recommendations were incorporated into the February 24 update to Immunize.org’s Ask the Experts: COVID-19 ([link removed]) page. Access the MMWR article in HTML ([link removed]) or PDF ([link removed]).
Related Links
* MMWR's main page ([link removed]) provides access to MMWR Weekly and its companion publications
* Immunize.org: ACIP Recommendations ([link removed]) main page
* Immunize.org: Ask the Experts COVID-19 ([link removed]) page
* Immunize.org: Vaccines: COVID-19 ([link removed]) main page
* Immunize.org: Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools ([link removed])
* CDC: Interim Clinical Considerations ([link removed]) page
------------------------------------------------------------
“Effectiveness of mRNA Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death—United States, March 2021–January 2022” published as an MMWR Early Release
CDC published Effectiveness of mRNA Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death—United States, March 2021–January 2022 ([link removed]) on March 18 as an MMWR Early Release. A portion of the summary appears below.
...Receiving 2 or 3 doses of an mRNA COVID-19 vaccine was associated with a 90% reduction in risk for COVID-19–associated IMV or death. Protection of 3 mRNA vaccine doses during the period of Omicron predominance was 94%....
The effectiveness of 2 or 3 doses of COVID-19 mRNA vaccines against COVID-19–associated invasive mechanical ventilation or in-hospital death was high for:
* People age 18–64 years (91%) and those older than age 64 years (88%)
* People who are immunocompetent (92%) and those who are immunocompromised (74%)
* Immunocompetent people with zero (98 %), one (95%), two (89%), or more than two (84%) chronic conditions
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]).
Related Link
* MMWR's main page ([link removed]) provides access to MMWR Weekly and its companion publications
------------------------------------------------------------
CDC revises two tables in its General Best Practice Guidelines for Immunization
On March 18, CDC updated the list of errata/updates ([link removed]) in its General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP) ([link removed]). The updates include the definitions of new terms used to describe vaccine categories (including non-live and non-replicating), and new information about contraindications to dengue vaccination. Specific information from CDC about the recent updates appears below.
Timing and Spacing of Immunobiologics
Table 3-1 (callout from PAGE 12)
A new table has been added (check renumbering if you’ve exported stand-alone documents). The new table highlights categories of vaccines (with callout from text on page 12). There are four categories: live; live-attenuated; non-live; and non-replicating. …
Contraindications and Precautions
Table 4-1
In the row for dengue vaccine, information has been added specifying that dengue vaccine should be used only in persons in endemic areas who have evidence of prior infection with dengue virus. Additionally, “Lack of laboratory evidence of previous dengue infection” has been added as a contraindication to dengue vaccine.
Related Link
* CDC: General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP) ([link removed])
------------------------------------------------------------
Order today! Laminated versions of CDC’s 2022 immunization schedules are available to ship.
Immunize.org laminated versions of the 2022 U.S. child and adolescent immunization schedule ([link removed]) and the 2022 U.S. adult immunization schedule ([link removed]) are available for preorder and will ship this week.
While the schedules are available online from CDC at no cost, Immunize.org’s printed, laminated schedules are ideal for use in any busy healthcare setting where vaccinations are given. Their tough coating can be wiped down, and they’re durable enough to stand up to a year's worth of use.
In 2022, the length of each schedule with appendices was extended by two pages. As a result, the laminated schedules are now published in a standard 8.5” X 11” booklet format.
* The child/adolescent schedule booklet is ten pages (i.e., five double-sided pages) and includes a bonus page with Immunize.org’s popular 1-page handout summarizing the dose, route, and needle size recommendations for all vaccines and recipients
* The adult schedule booklet is eight pages (i.e., four double-sided pages)
With color coding for easy reading, our laminated schedules replicate the original CDC formatting, including the essential tables and notes.
PRICING
Number of Copies Cost
1–4 copies $7.50 each
5–19 copies $5.50 each
20–99 copies $4.50 each
100–499 copies $4.00 each
500–999 copies $3.50 each
For quotes on customizing or placing orders of 1,000 copies or more, call 651-647-9009 or email [email protected].
Visit the Shop Immunize.org: Laminated Schedules ([link removed]) web page for more information on the schedules, to view images of all the pages, to download the order form, and to order today!
Related Links
* Immunize.org: Laminated Child and Adolescent Immunization Schedules (0–18 years) ([link removed]) web page
* Immunize.org: Laminated Adult Immunization Schedules (19 and older) ([link removed]) web page
* Immunize.org: Shop Immunize.org ([link removed]) main page
------------------------------------------------------------
Spotlight: Review of resources at Immunize.org focused on communications
In this week's Immunize.org Spotlight, we summarize resources at Immunize.org that focus on communication between healthcare personnel, patients, and caregivers.
Immunize.org's Talking about Vaccines ([link removed]) web section provides healthcare professionals with 11 topical web pages to help them discuss immunization with concerned parents or patients. Examples include “Adjuvants,” “Alternative Medicine,” “Autism,” “Religious Concerns,” and “Thimerosal.”
Unprotected People Stories ([link removed]) features 109 real-life accounts of people who suffered or died from vaccine-preventable diseases.
Handouts for Patients and Staff ([link removed]) leads to hundreds of patient handouts and fact sheets for healthcare professionals. All items are free to download, print, copy, and distribute widely.
Ask the Experts ([link removed]) provides more than 1,100 timely questions and answers on specific diseases and their vaccines as well as vaccine delivery guidance (e.g., administration, billing, documenting).
Vaccine Basics: Common Questions about Vaccines ([link removed]) offers patients and caregivers timely, accurate, and factual information about vaccines and the diseases they prevent.
------------------------------------------------------------
AAP posts analysis of COVID-19 vaccination trends in U.S. children and adolescents
Drawing on data collected and published by CDC, AAP is analyzing progress in vaccinating U.S. children younger than age 18 years in a new weekly summary report titled Children and COVID-19 Vaccinations Trends ([link removed]). The report covers the vaccine data available for children age 5–11 years, and the longer-term data for children age 12–17 years.
To download the full report with its useful graphics, click on the image below.
[link removed]
Related Links
* AAP: Children and COVID-19 Vaccinations Trends ([link removed]) report web page
* AAP: Children and COVID-19 Vaccinations Trends ([link removed]) full report
* CDC: COVID Data Tracker ([link removed]) main page
------------------------------------------------------------
Influenza activity is low overall, but continues to increase in some parts of the country. Keep offering to vaccinate.
Influenza Surveillance
For week 9, ending on March 5, CDC's Weekly U.S. Influenza Surveillance Report, FluView ([link removed]) summary reports that seasonal influenza activity in the United States is low but continues its gradual increase in parts of the country. The levels of acute respiratory illness reflected in the national map include both influenza and non-influenza (e.g., COVID-19) respiratory illnesses.
Influenza Vaccination Dashboard
CDC's new Weekly Flu Vaccination Dashboard ([link removed]) shares preliminary vaccination data. This week’s key fact: coverage this season (as of February 12) is 11.0 percentage points lower for non-Hispanic Black children compared with non-Hispanic White children (42.9% compared to 53.9%).
CDC recommends everyone age 6 months and older get an annual influenza vaccine. Influenza and COVID-19 vaccines may be given at the same visit, if needed. COVID-19 vaccination alone provides no protection from influenza or any other respiratory virus.
Vaccine Finder
If you don’t provide influenza vaccine at your site, please strongly recommend vaccination and refer people to sites that do vaccinate. Use VaccineFinder, a user-friendly website to help people of all ages find influenza, COVID-19, and other vaccines ([link removed]). Participating providers can update their vaccine inventory estimates on VaccineFinder. For questions or more information, contact [email protected].
Related Links
* CDC: Weekly Flu Vaccination Dashboard ([link removed]) main page
* CDC: FluView ([link removed]) main page
* CDC: Influenza (Flu) ([link removed]) main page
* Immunize.org: free educational materials and patient handouts related to influenza ([link removed])
* Immunize.org: Vaccines: Influenza ([link removed]) main page
* Immunize.org: Ask the Experts: Influenza ([link removed]) main page
* VaccineFinder ([link removed]) website
* Families Fighting Flu: Flu Resources for Healthcare Professionals ([link removed]) main page
------------------------------------------------------------
Immunize.org’s Hepatitis B Birth Dose Honor Roll recognizes 546 institutions, including one new honoree. Six previously honored institutions qualify for additional years' honors.
Immunize.org is pleased to announce that one new institution has been accepted into its Hepatitis B Birth Dose Honor Roll ([link removed]), for a total of 546 honorees. The birthing institutions are listed below with their reported hepatitis B birth dose coverage rates in parentheses.
* Erlanger Medical Center, Chattanooga, TN (95%)
One institution is being recognized for a second year:
* Bellevue Woman’s Center, Niskayuna, NY (94%)
Three institutions are being recognized for a fourth year:
* Central Vermont Medical Center, Berlin, VT (93%)
* HealthPark Medical Center, Ft. Myers, FL (90%)
* Lawrence General Hospital, Lawrence, MA (98%)
One institution is being recognized for a fifth year:
* RAF Lakenheath Hospital (U.S. Air Force), Brandon, England (93%)
Finally, one institution is being recognized for a sixth year:
* Integris Grove Hospital, Grove, OK (96%)
The Honor Roll now includes 546 birthing institutions from 44 states, the District of Columbia, Puerto Rico, Guam, Saipan, and a U.S. military base in England. One hundred twenty-three institutions have qualified for two years, 71 institutions have qualified three times, 42 institutions have qualified four times, 26 institutions have qualified five times, 23 institutions have qualified six times, 11 institutions have qualified seven times, two institutions have qualified eight times and one institution has qualified nine times.
The Honor Roll is a key part of Immunize.org’s major initiative urging the nation’s hospitals to Give Birth to the End of Hep B ([link removed]) . Hospitals and birthing centers are recognized for attaining high coverage rates for administering hepatitis B vaccine at birth and meeting specific additional criteria. The initiative urges qualifying healthcare organizations to apply for the Hepatitis B Birth Dose Honor Roll online ([link removed]).
To be included in the Hepatitis B Birth Dose Honor Roll, a birthing institution must have: (1) reported a coverage rate of 90% or greater, over a 12-month period, for administering hepatitis B vaccine before hospital discharge to all newborns, including those whose parents refuse vaccination, and (2) implemented specific written policies, procedures, and protocols to protect all newborns from hepatitis B virus infection before hospital discharge.
Honorees are also awarded an 8.5" x 11" color certificate suitable for framing and their acceptance is announced to IZ Express’s 53,000+ readers.
Please visit the Hepatitis B Birth Dose Honor Roll web page ([link removed]) that lists these institutions and their exceptional efforts to protect infants from perinatal hepatitis B transmission.
Related Immunize.org Resources
* Give Birth to the End of Hep B ([link removed]) main page
* Fact sheet about honor roll: Do You Qualify for the Hepatitis B Birth Dose Honor Roll? If So, Apply Today. ([link removed])
* Handout on Immunize.org’s campaign: Give Birth to the End of Hep B ([link removed])
* Hepatitis B Birth Dose Honor Roll ([link removed]) web page
------------------------------------------------------------
Vaccines in the news
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
* The Atlantic: America’s Flu-Shot Problem Is Also Its Next COVID-Shot Problem ([link removed]) (3/18/22)
* Washington Post: Moderna Seeks FDA Authorization for a Second Booster Dose of Its Coronavirus Vaccine for All Adults ([link removed]) (3/17/22)
* New York Times: As Virus Data Mounts, the J.&J. Vaccine Holds Its Own ([link removed]) (3/15/22)
* Becker's Hospital Review: Pfizer Seeks 2nd Booster Shot OK for People 65 and Older ([link removed]) (3/15/22)
* New York Times: In Africa, a Mix of Shots Drives an Uncertain COVID Vaccination Push ([link removed]) (3/15/22)
* The Atlantic: Vaccinating Kids Has Never Been Easy ([link removed]) (3/10/22)
------------------------------------------------------------
Immunize.org Pages and Handouts
------------------------------------------------------------
Reminder: Immunize.org updates two of its popular standing order templates with new CDC recommendations: pneumococcal vaccination of adults and zoster (shingles) vaccination
Immunize.org recently revised its Standing Orders for Administering Pneumococcal Vaccines (PCV15, PCV20, and PPSV23) to Adults ([link removed]) and Standing Orders for Administering Recombinant Zoster Vaccine to Adults ([link removed]) templates.
The Standing Orders for Administering Pneumococcal Vaccines (PCV15, PCV20, and PPSV23) to Adults ([link removed]) template incorporates the new CDC recommendations published in January 2022. This template covers the use of 15-valent pneumococcal conjugate vaccine (PCV15, Vaxneuvance, Merck), PCV20 (Prevnar20, Pfizer), and 23-valent pneumococcal polysaccharide vaccine (PPSV23, Pneumovax 23, Merck). The document outlines what to do for previously unvaccinated adults, as well as adults with a history of vaccination with PCV13 and/or PPSV23.
The Standing Orders for Administering Recombinant Zoster Vaccine to Adults ([link removed]) template was updated with information on the new CDC recommendations for use of recombinant zoster vaccine (RZV, Shingrix, GSK) in adults age 19 and older who are or will be immunodeficient or immunosuppressed as a result of disease or therapy. For patients in this category, the standing orders recommend consultation with the medical director and—as needed—the provider primarily responsible for managing the patient’s immunocompromising condition or therapy. This is because the complex and highly variable nature of immunocompromising conditions may affect the optimal timing of vaccination.
Related Links
* Immunize.org: Standing Orders for Administering Pneumococcal Vaccines (PCV15, PCV20, and PPSV23) to Adults ([link removed])
* Immunize.org: Standing Orders for Administering Recombinant Zoster Vaccine to Adults ([link removed])
* Immunize.org: Using Standing Orders for Administering Vaccines: What You Should Know ([link removed])
* Immunize.org: 10 Steps to Implementing Standing Orders for Immunization in Your Practice Setting ([link removed])
* Immunize.org: Standing Orders Templates for Administering Vaccines ([link removed]) web page
* Immunize.org: Ask the Experts: Zoster ([link removed]) web page
------------------------------------------------------------
Reminder: "Ask the Experts: Zoster" web page updated with new clinical considerations for vaccination of immunocompromised adults age 19 and older
Immunize.org thoroughly reviewed and updated its popular Ask the Experts: Zoster ([link removed]) web page on March 9. This extensive list of clinical questions and answers was updated to incorporate new ACIP recommendations and clinical considerations for the use of recombinant zoster vaccine (RZV, Shingrix, GSK) in adults age 19 years and older who are or will be immunodeficient or immunosuppressed as a result of disease or therapy. The section addresses challenging clinical questions, such as:
* Do immunocompromised adults need to be screened for immunity to varicella zoster virus?
* What do I do with an adult who never had chickenpox and only had one dose of varicella vaccine?
* Should I shorten the dosing interval if a person knows they will be starting chemotherapy soon?
Immunize.org's Ask the Experts ([link removed]) main page leads you to 30 distinct web pages on a variety of topics with more than 1,100 common or challenging questions and answers about vaccines and their administration. Immunize.org's team of experts includes Kelly L. Moore, MD, MPH (team lead), Carolyn B. Bridges, MD, FACP, and Iyabode Beysolow, MD, MPH.
Related Links
* Immunize.org: Ask the Experts: Zoster ([link removed]) web page
* Immunize.org: Ask the Experts ([link removed]) main page to answer more than 1,100 questions
------------------------------------------------------------
Vaccine Information Statements
------------------------------------------------------------
Reminder: Immunize.org posts new Vaccine Information Statements (VISs) in nine languages for pneumococcal conjugate vaccine (PCV) and recombinant zoster (shingles) vaccine
Immunize.org posted new translations of Vaccine Information Statements ([link removed]) (VISs) for Pneumococcal Conjugate Vaccine (PCV) and Recombinant Zoster (shingles) Vaccine.
All translations are available in print-ready PDF format.
VIS translations for Pneumococcal Conjugate Vaccine (PCV) ([link removed]):
* Arabic ([link removed])
* Burmese ([link removed])
* Chinese in Simplified ([link removed]) and Traditional ([link removed])
* French ([link removed])
* Russian ([link removed])
* Somali ([link removed])
* Spanish PDF ([link removed]) and RTF ([link removed])
* Vietnamese ([link removed])
VIS translations for Recombinant Zoster (shingles) Vaccine ([link removed]):
* Arabic ([link removed])
* Burmese ([link removed])
* Chinese in Simplified ([link removed]) and Traditional ([link removed])
* French ([link removed])
* Russian ([link removed])
* Somali ([link removed])
* Spanish PDF ([link removed]) and RTF ([link removed])
* Vietnamese ([link removed])
Translations of previous VIS versions may be used until new translations become available. CDC states that the corresponding up-to-date English-language VIS must also be supplied when providing an out-of-date translation.
Related Links
* Immunize.org: Vaccine Information Statement ([link removed]) main page for VISs in 46 languages ([link removed])
* Immunize.org: Dates of Current Vaccine Information Statements ([link removed]) (PDF)
* CDC: What's New with VISs ([link removed]) web page
* CDC: Current VISs ([link removed]) web page
------------------------------------------------------------
Featured Resources
------------------------------------------------------------
65+ Flu Defense website offers resources for healthcare professionals serving older adults
Confident recommendations for influenza vaccine from healthcare providers are powerfully persuasive. To assist you in maximizing protection for your patients, Immunize.org, in collaboration with Seqirus, updated the 65+ Flu Defense website at www.influenza-defense.org.
A fact sheet on the site, ([link removed]) The Importance of Preventing Influenza during a Pandemic, ([link removed]) ([link removed]) offers responses to help guide discussions with patients on the increased importance of flu vaccination during the COVID-19 pandemic. Age increases risks associated with COVID-19 infection including hospitalization and death. Preliminary studies suggest coinfection with influenza B and SARS-CoV-2 may elevate the risk of poor outcomes.
This helpful site includes information, tools, and tips for communicating with these adults about the scope and severity of influenza. Resources include:
* Influenza in Adults 65+: The Facts ([link removed])
* Influenza Vaccination: Questions Patients Age 65 and Older Frequently Ask Their HCP ([link removed])
Check out the updated 65+ Flu Defense website at www.influenza-defense.org ([link removed]) to assist your efforts in protecting this vulnerable population.
------------------------------------------------------------
Notable Publications
------------------------------------------------------------
"Trends in Human Papillomavirus–Associated Cancers, Demographic Characteristics, and Vaccinations in the U.S., 2001–2017" published in JAMA Network
In the March 16 issue, JAMA Network published Trends in Human Papillomavirus–Associated Cancers, Demographic Characteristics, and Vaccinations in the U.S., 2001–2017 ([link removed]). Before vaccination approval, cervical cancer rates in the 20- to 24-year age group were decreasing very gradually, by 2.29% annually; after vaccine approval, this rate of decrease accelerated to 9.50% annually.
The conclusions and relevance section appears below.
In the US, cervical cancer rates have decreased at a population level, especially in younger women. The findings of this study suggest this decrease may be associated with vaccination. Given the increase in oropharyngeal and anal/rectal cancers, particularly in men, it may be important to highlight vaccination uptake in both sexes.
Listen to an interview with John K. Chan, MD ([link removed]), author of this article, hosted by Angel N. Desai, MD, MPH (16:23 minutes).
------------------------------------------------------------
Upcoming Events
------------------------------------------------------------
Virtual: Nevada Immunization Learning Exchange offers webinar, “Overview for Parents and Caregivers: The COVID-19 Vaccine for Children and Youth with Special Health Care Needs including Children Living with Intellectual and Developmental Disabilities,” on March 29
Nevada Immunization Learning Exchange (NILE) will offer a webinar titled Overview for Parents and Caregivers: The COVID-19 Vaccine for Children and Youth with Special Health Care Needs including Children Living with Intellectual and Developmental Disabilities ([link removed]) on March 29 at 6:00 p.m. (PT). During this program, there will be a discussion on the impact of COVID-19 on children and youth with special healthcare needs, including children living with intellectual and developmental disabilities.
Registration is open ([link removed]) for this webinar.
------------------------------------------------------------
For more upcoming events, visit our Calendar of Events ([link removed]).
Editorial Information
Editor-in-Chief
Kelly L. Moore, MD, MPH
Managing Editor
John D. Grabenstein, RPh, PhD
Associate Editor
Sharon G. Humiston, MD, MPH
Writer/Publication Coordinator
Taryn Chapman, MS
Courtnay Londo, MA
Style and Copy Editor
Marian Deegan, JD
Web Edition Managers
Arkady Shakhnovich
Jermaine Royes
Contributing Writer
Laurel H. Wood, MPA
Technical Reviewer
Robin VanOss
About IZ Express
Immunize.org welcomes redistribution of this issue of IZ Express or selected articles.
When you do so, please add a note that Immunize.org is the source of the material and provide a link to this issue ([link removed]).
IZ Express is supported in part by Grant No. 1NH23IP922654 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.
IZ Express Disclaimer ([link removed])
ISSN: 2771-8085
To unsubscribe to this publication, go to: [link removed]
==============================================
Unsubscribe [email protected] from this list:
[link removed]
Message Analysis
- Sender: Immunization Action Coalition
- Political Party: n/a
- Country: United States
- State/Locality: n/a
- Office: n/a
-
Email Providers:
- MailChimp